Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Tryptamine Therapeutics ( (AU:TYP) ) has issued an announcement.
Tryptamine Therapeutics Limited announced the quotation of 165,588,237 ordinary fully paid securities on the Australian Securities Exchange (ASX) as of November 18, 2025. This move is part of previously announced transactions and could enhance the company’s market presence and liquidity, potentially benefiting stakeholders by increasing access to capital and expanding its investor base.
More about Tryptamine Therapeutics
Tryptamine Therapeutics Limited operates in the pharmaceutical industry, focusing on the development and commercialization of therapeutic products. The company is primarily engaged in creating innovative treatments, potentially targeting mental health and neurological conditions.
Average Trading Volume: 2,495,811
Technical Sentiment Signal: Buy
Current Market Cap: A$51.98M
For detailed information about TYP stock, go to TipRanks’ Stock Analysis page.